Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5 for postoperative inflammation

Loteprednol etabonate 0.5% led to a clinically meaningful reduction in the signs and symptoms of postoperative ACI and had an acceptable safety profile when compared with a placebo.